DexCom, Inc. $DXCM Shares Purchased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 41.6% in the 2nd quarter, Holdings Channel.com reports. The firm owned 48,453 shares of the medical device company’s stock after purchasing an additional 14,225 shares during the period. Nisa Investment Advisors LLC’s holdings in DexCom were worth $4,229,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of DXCM. Brighton Jones LLC lifted its holdings in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares during the period. Golden State Wealth Management LLC lifted its holdings in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after purchasing an additional 264 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of DexCom by 558.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 385,594 shares of the medical device company’s stock worth $25,958,000 after purchasing an additional 327,023 shares during the period. Amalgamated Bank lifted its holdings in shares of DexCom by 2.7% during the first quarter. Amalgamated Bank now owns 83,082 shares of the medical device company’s stock worth $5,674,000 after purchasing an additional 2,176 shares during the period. Finally, Mather Group LLC. lifted its holdings in shares of DexCom by 135.5% during the first quarter. Mather Group LLC. now owns 1,109 shares of the medical device company’s stock worth $76,000 after purchasing an additional 638 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DXCM has been the subject of several research analyst reports. William Blair upgraded DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Raymond James Financial increased their price objective on DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 31st. Robert W. Baird cut their price objective on DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a research report on Friday, September 26th. Morgan Stanley increased their price objective on DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Finally, Citigroup cut their price objective on DexCom from $105.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $97.19.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares in the company, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This represents a 1.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 5,383 shares of company stock worth $434,274. Corporate insiders own 0.32% of the company’s stock.

DexCom Trading Down 1.5%

NASDAQ:DXCM opened at $68.18 on Thursday. The company has a market capitalization of $26.74 billion, a PE ratio of 47.35, a price-to-earnings-growth ratio of 1.45 and a beta of 1.47. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The stock has a fifty day simple moving average of $71.67 and a 200-day simple moving average of $78.03.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business’s revenue was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.43 EPS. On average, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.